High Intensity Interval Training in Prediabetes

Not Applicable

• Conditions: Prediabetic State
• Interventions: Behavioral: High intensity interval training (HIIT); Behavioral: Moderate intensity continuous training (MICT)

• Registration Number: NCT03773731
• Lead Sponsor: Medical University of Vienna

Brief Summary

This trial investigates if high intensity interval training is more effective than moderate intensity continuous training in suppressing platelet reactivity and hepatic fat content in prediabetic individuals.

Detailed Description

Background:

The prevalence of type 2 diabetes mellitus (T2DM) is rising dramatically. T2DM represents a major cause for cardiovascular disease -related mortality and morbidity and increasingly burdens healthcare systems. While the fundamental pathomechanism of T2DM is insulin resistance of muscle and adipose tissue, recent studies demonstrate that insulin resistance in T2DM also occurs in platelets. As insulin directly inhibits platelet function, this mechanism might contribute to platelet activation and platelet hyperreactivity, which were in fact detected in diabetic patients. Since (inadvertent) platelet activation is causally linked to the development of atherosclerosis and atherothrombosis, regulation of platelet function is of utmost importance. Exercise training, performed on a regular basis has been shown to reduce morbidity and mortality in sedentary and diseased populations. Furthermore, exercise training improves whole body insulin sensitivity - however, it is currently unclear, if exercise training also affects insulin sensitivity of platelets. Recently, a time-saving interval training protocol has been adapted for T2DM-patients. Since this adapted high intensity interval training (HIIT) needs a fractional time commitment of exercise training according to current guidelines, HIIT possibly represents a promising instrument to increase adherence to exercise and thereby reduce T2DM morbidity.

Aims:

The primary aim of this study is to investigate the effect of 12 weeks of HIIT vs. continuous training (CT) on platelet insulin sensitivity and platelet (hyper)reactivity in prediabetic patients.

Secondary aims are to assess the effect of HIIT and CT on whole body insulin sensitivity and fitness in prediabetic patients as well as on various parameters of platelet function and on the hepatic fat content.

Hypotheses:

Our main hypothesis is that HIIT increases platelet insulin sensitivity and thereby decreases platelet activation/reactivity in patients with prediabetes. Methods: 44 prediabetic (see inclusion criteria) patients will be enrolled in this study. Patients will randomly be assigned to a HIIT group (committed to a supervised training program) or a CT group. After initial examinations (supervised graded exercise test, platelet function tests, oral glucose tolerance test, measurement of the hepatic fat content via FibroScan®), supervised training will be performed over a period of 12 weeks. Tests performed at the beginning of the study will be repeated after the training period.

Study Timeline

• Study First Submitted: 2018-12-10
• Study First Submitted QC: 2018-12-11
• Study First Posted: 2018-12-12
• Status Verified: 2019-01
• Study Start: 2019-01-04
• Last Update Submitted: 2019-01-07
• Last Update Posted: 2019-01-09
• Primary Completion: 2020-12
• Study Completion: 2021-02

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Male
• Target Recruitment: 44

Inclusion Criteria

• prediabetic (insulin-insensitive) patients
• either fasting plasma glucose 100- 125 mg/dl or HbA1c 5.7 - 6.4
• < 3kg bodyweight change within the last 6 months

Read More

Exclusion Criteria

• Any contraindications for exercise
• resulting from anamnesis ( e.g. history of angina pectoris, peripheral arterial disease), ECG at rest or during graded exercise test, echocardiogram, echocardiography or lung function test
• chronical joint pain that makes exercise training on bicycle ergometers impossible
• any conditions that make the successful participation in the study unlikely
• islet cell autoantibodies
• Medication: insulin, thiazolidindiones, statins, antidepressants
• Secondary diseases: History of end-stage liver or kidney disease; pronounced neuropathy or retinopathy
• drug or alcohol abuse

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
High intensity interval training	High intensity interval training (HIIT)	3x/week the following 45 min training protocol on bicycle ergometer for 12 weeks: * 5 minutes warm-up phase with a power output of 40% of the maximal power output achieved in an incremental exercise test * 30 minutes: intensive cycling bouts of 60s interspersed with 60s of recovery intervals. Power output will be 90% (week 1-6) or 95% (week 7-12) of the maximal power output of the exercise test during the intensive cycling bouts. During recovery intervals, subjects will pedal with a power output of 30% (week 1-6) or 35% (week 7-12) of the maximal power output of the exercise test. * 10 minutes with 30% of maximal power output.
Moderate intensity continuous training	Moderate intensity continuous training (MICT)	3x/week the following 45 min training protocol on bicycle ergometer for 12 weeks: * 5 minutes warm-up phase with a power output of 40% of the maximal power output achieved in an incremental exercise test * 30 minutes: Continuous training with 60% (week 1-6) or 65% (week 7-12) of maximal power output * 10 minutes with 30% of maximal power output.

Primary Outcome Measures

Name	Time	Method
EC50 (half-maximal effective concentration) of TRAP-6 (thrombin-receptor activating peptide) in terms of surface CD62P (=platelet selectin, P-selectin) expression: group differences after 12 weeks of training	12 weeks
EC50 of insulin in terms of intraplatelet VASP (vasodilator-stimulated phosphoprotein)-phosphorylation: group differences after 12 weeks of training	12 weeks

Secondary Outcome Measures

Name	Time	Method
Maximal oxygen consumption	12 weeks	Unit: ml/min/kg bodymass
whole body insulin sensitivity	12 weeks
EC50 of other platelet agonists in terms of various platelet activation markers	12 weeks
EC50 of prostacyclin in terms of intraplatelet VASP-phosphorylation	12 weeks
Transient elastography (FibroScan®) controlled attenuation parameter (CAP)	12 weeks	The controlled attenuation parameter (CAP) has demonstrated good accuracy in quantifying the levels of liver steatosis and fibrosis in patients with NAFLD
Fatty Liver Index (FLI)	12 weeks

Trial Locations

Locations (1)

MUVienna; 🇦🇹 Vienna, Austria